Lot-document scope confirmed before quotation · Research use only
  • Specification Review
  • Lot Documents on Request
  • Business Support · Xi’an
  • Destination Eligibility Confirmed
西安诺和达生物科技有限公司
For research, development and manufacturing use only. Not for human or veterinary use.

Cognitive & Neuropeptides · Source-reviewed dossier

VIP

Source-Reviewed Research Dossier

VIP is a small signaling peptide the body makes naturally in nerves and immune cells. It helps widen blood vessels, release fluid from glands, and adjust immune-cell activity through two receptors, VPAC1 and VPAC2. Because this signaling system touches the gut, circulation and inflammation, researchers use VIP as a laboratory tool. The studies collected here are an immune review and preclinical experiments in gut cells and mice after radiation injury. They describe mechanisms and model-specific findings, not human treatment results. They do not show whether any particular supplied material is pure, correctly identified or active.

Research use only Lot documents on request
VIP research product family with 2 catalog variants
AI-generated packaging mockup for catalog navigation. It is not a photograph of an actual supplied lot; container, label and presentation may vary.

Product family

Compound overview

Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.

Product identity

Product type
Peptide research compound
Catalog family
VIP
Research category
Cognitive & Neuropeptides
Catalog CAS RN
37221-79-7
Catalog molecular formula
C147H238N44O42S
Catalog molecular weight
3325.85 g/mol
Catalog sequence
His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
Evidence status
Established endogenous physiology with mainly preclinical therapeutic research
Intended use
Research, development and manufacturing use only

Literature reference parameters

Compound or material class
Vasoactive intestinal peptide / PACAP-receptor-family ligandCatalog-family identity
Evidence scope
Established endogenous physiology with mainly preclinical therapeutic researchDo not generalize beyond the cited model
Source review
Primary or authoritative records linked belowChecked 2026-09-01

Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.

Mechanism of action

How VIP is studied

A target-to-pathway view grounded in the linked research records.

How VIP acts on cells

VIP binds VPAC1 and VPAC2, receptors on cell surfaces. This switches on cAMP, a messenger inside the cell that changes its behavior. Blood vessels relax and widen, glands release fluid, and immune cells adjust their activity. Because these receptors appear on many cell types, one peptide can influence several body systems. That broad reach is why VIP is studied, and also why simple claims about it are unreliable.

Wide immune effects, seen in a review

An immune review describes VIP effects on both rapid, non-specific immune responses and targeted, antibody-based ones. VIP is released by nerve endings and immune cells themselves. Immune cells also carry VIP receptors, so the peptide is part of the same conversation it regulates. This breadth explains interest in inflammatory and autoimmune conditions. However, a review collects existing observations. It did not test any supplied peptide or show that giving VIP to a person changes disease outcomes.

Gut lining and radiation injury in the lab

In intestinal organoids, miniature lab-grown gut tissue, VIP pushed immature cells toward a secretory identity, largely through a stress-signaling route called p38 MAPK. It also changed how quickly these cells divided. After radiation damage, the same treatment supported tissue regrowth. In mice given abdominal radiation, injected VIP reduced injury markers. These are controlled preclinical experiments with specific cells, doses and routes, so they describe a research model, not a proven human therapy.

What these studies do not cover

Published biology and animal studies say nothing about the purity, identity or handling of a commercial research vial. A catalog listing, a purity report and a biological finding answer three different questions. Existing product documents control identity and lot release. The reference studies control statements about mechanism and model-specific outcomes. Keeping these layers apart is why this page reports both the promising preclinical recovery findings and the plain fact that human therapeutic evidence is not supplied here.

Reported research findings

What published studies report about VIP

Reported outcomes are paired with their experimental model and evidence boundary.

Immunology review

VIP has pleiotropic immune functions

A review summarized VIP effects across innate and adaptive immune-cell pathways.

A mechanistic review does not establish efficacy for a supplied peptide material.

Read the primary study
Animal injury model

Intestinal-radiation outcomes were preclinical

A 2024 study reported secretory-differentiation and injury outcomes in radiation-exposed intestinal models.

The model does not establish human treatment or catalog-lot quality.

Read the primary study
Translation boundary: findings are limited to the evidence level stated on each card. Experimental protocol quantities are research details, not usage instructions.

Catalog options

Variant specifications

Pack-level catalog data; lot-level controls remain document-specific.

Catalog no.VIP5
Pack size5 mg × 10 vials
Specification & documents for VIP5

Product specification

Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.

Lot documentation

Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.

Catalog no.VIP10
Pack size10 mg × 10 vials
Specification & documents for VIP10

Product specification

Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.

Lot documentation

Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.

Quality system

Quality documentation

A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.

Lot-specific Certificate of AnalysisAvailability and scope must be confirmed for the selected catalog variant and lot
COA availability unconfirmed Ask about availability
Product Specification SheetAvailability and scope must be confirmed for the selected catalog variant and lot
Confirm before ordering Request
Analytical Method SummaryAvailability and scope must be confirmed for the selected catalog variant and lot
Confirm before ordering Request

Analytical interpretation

Interpret the documents, not just the headline number.

Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.

Open the Quality & Documentation Hub

HPLC area ≠ assayA dominant peak does not establish target mass fraction.

Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.

Counterions affect contentWater, salt form and solvents change the as-is composition.

Storage needs a data basisShipping practice is not the same as stability evidence.

Evidence map

Research context

Published studies and regulatory records, not customer testimonials or usage guidance.

Immunology review

VIP has pleiotropic immune functions

A mechanistic review does not establish efficacy for a supplied peptide material.

View primary record
Animal injury model

Intestinal-radiation outcomes were preclinical

The model does not establish human treatment or catalog-lot quality.

View primary record
Evidence boundary: each card states its evidence type. Human trials and regulatory records describe the studied or regulated intervention; preclinical records remain model-specific. None verifies the identity, quality, safety or efficacy of this catalog lot or provides usage instructions.

Literature basis

Curated references

Third-party publications selected for direct relevance.

  1. 01 Immunology review
  2. 02 Animal injury model

Research FAQ

VIP questions

Concise answers for researchers comparing identity, evidence and catalog variants.

What effects are studied for VIP?

Two directions stand out. A review maps VIP as a wide-ranging immune regulator acting through VPAC receptors and cAMP. A preclinical study found VIP nudged intestinal cells toward a secretory fate, altered progenitor-cell division, and lessened radiation injury in organoids and in mice given abdominal radiation. These describe mechanism and model outcomes, not confirmed benefits for people. Neither finding speaks to the quality, purity or performance of any particular catalog material.

How should the VIP research findings be understood?

Published biology and animal studies say nothing about the purity, identity or handling of a commercial research vial. A catalog listing, a purity report and a biological finding answer three different questions. Existing product documents control identity and lot release. The reference studies control statements about mechanism and model-specific outcomes. Keeping these layers apart is why this page reports both the promising preclinical recovery findings and the plain fact that human therapeutic evidence is not supplied here.

What evidence is available for VIP?

The evidence base is broad in physiology but therapeutic intervention evidence remains indication-specific and frequently preclinical.

Does the cited research validate this catalog material?

No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.

Which quality documents can be requested?

A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.

How should VIP be stored?

Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.

Knowledge center

Related insights

Owned educational content connected to this family.

Knowledge tools

Continue with structured evidence

Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.

Internal technical source review

Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.

Editorial status: NHD evidence editorial workflow · 2026-09-01 · Not independent medical review · Review policy

Technical procurement

Ready to request a quote?

Selected: VIP5 · 5 mg × 10 vials